Sarepta Therapeutics Announces Positive Vote from US FDA Advisory Committee Meeting for SRP9001 Gene Therapy to Treat Duchenne Muscular Dystrophy 51223  Advisory committee voted 86 in support of accelerated approval of SRP9001  Regulatory action date is May 29 2023 CAMBRIDGE Mass